GC-012F

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug NameGC-012F
Drug Alias NameBCMA-Antigen X Bispecific CAR-Modified T Cells-Gracell-BiotechnologyBCMA-Antigen X bispecific CAR-T cellsDual CAR-BCMA-19FasTCAR-T GC012FBCMA/CD19 dual-target CAR-T cell immunotherapy(Gracell Biotechnology) +[12] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapy
Mechanisms of ActionAnti-CD19Anti-BCMA
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsAmyloidosisScleroderma, SystemicLupus Erythematosus, Systemic +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[15] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGracell Biotechnologies (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSuzhou Genxi Biotechnology Co LtdTongji HospitalAstrazeneca Plc +[6] 
Inactive CompaniesHuashan HospitalZhejiang UniversityGracell Biotechnology Ltd
Active IndicationsAmyloidosisScleroderma, SystemicLupus Erythematosus, Systemic +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A